Several other research firms have also recently commented on LGND. Guggenheim started coverage on Ligand Pharmaceuticals in a research note on Monday, March 9th. They set a “neutral” rating for the company. HC Wainwright reissued a “buy” rating and set a $237.00 target price on shares of Ligand Pharmaceuticals in a research note on Wednesday, February 12th. Roth Capital lowered their target price on Ligand Pharmaceuticals from to and set a “buy” rating for the company in a research note on Monday, February 10th. ValuEngine raised Ligand Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 1st. Finally, Benchmark reissued a “buy” rating and set a $135.00 target price on shares of Ligand Pharmaceuticals in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $153.17.
LGND opened at $72.92 on Friday. Ligand Pharmaceuticals has a 12 month low of $57.24 and a 12 month high of $130.50. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of 2.49, a PEG ratio of 2.18 and a beta of 1.18. The company has a debt-to-equity ratio of 0.85, a current ratio of 66.09 and a quick ratio of 65.66. The business has a fifty day moving average price of $92.32 and a 200 day moving average price of $99.90.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Thursday, February 6th. The biotechnology company reported $0.71 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.07. Ligand Pharmaceuticals had a return on equity of 4.34% and a net margin of 523.19%. The firm had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.30 million. During the same period in the previous year, the firm posted $1.70 EPS. Ligand Pharmaceuticals’s revenue for the quarter was down 54.7% on a year-over-year basis. On average, research analysts anticipate that Ligand Pharmaceuticals will post 2.27 earnings per share for the current year.
In other news, COO Matthew W. Foehr sold 7,225 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $110.00, for a total transaction of $794,750.00. Following the completion of the transaction, the chief operating officer now directly owns 160,968 shares of the company’s stock, valued at approximately $17,706,480. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 8.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in shares of Ligand Pharmaceuticals by 14.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,248 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 159 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Ligand Pharmaceuticals by 18.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,260 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 200 shares in the last quarter. Woodstock Corp boosted its position in shares of Ligand Pharmaceuticals by 0.3% during the 4th quarter. Woodstock Corp now owns 71,489 shares of the biotechnology company’s stock worth $7,456,000 after acquiring an additional 241 shares in the last quarter. FSA Wealth Management LLC acquired a new position in shares of Ligand Pharmaceuticals during the 4th quarter worth about $26,000. Finally, Blair William & Co. IL boosted its position in shares of Ligand Pharmaceuticals by 0.9% in the 4th quarter. Blair William & Co. IL now owns 28,825 shares of the biotechnology company’s stock valued at $3,006,000 after purchasing an additional 266 shares during the period.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Further Reading: Cost of Debt
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.